Diagnosis, prognosis, and management of leiomyosarcoma: Recognition of anatomic variants

Current Opinion in Oncology

Volumn 25, Issue 4, 2013, Pages 384-389

  Bathan, Andrew J ^a   Constantinidou, Anastasia ^b   Pollack, Seth M ^a   Jones, Robin L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

leiomyosarcoma; management; sarcoma; uterine; variants

Indexed keywords

BEVACIZUMAB; CALDESMON; DACARBAZINE; DESMIN; DOCETAXEL; DOXORUBICIN; EPITHELIAL MEMBRANE ANTIGEN; ERIBULIN; ESTROGEN RECEPTOR; GEMCITABINE; IFOSFAMIDE; KERATIN; KI 67 ANTIGEN; PAZOPANIB; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; RIDAFOROLIMUS; SMOOTH MUSCLE ACTIN; SOMATOMEDIN B; SORAFENIB; TRABECTEDIN;

ANATOMICAL VARIATION; BONE CANCER; BONE LEIOMYOSARCOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS LEIOMYOSARCOMA; ECHOGRAPHY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MAINTENANCE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL CANCER; RETROPERITONEAL LEIOMYOSARCOMA; REVIEW; SKIN CANCER; SYSTEMIC THERAPY; TREATMENT OUTCOME; UTERINE LEIOMYOSARCOMA; UTERUS CANCER; VASCULAR DISEASE; VASCULAR LEIOMYOSARCOMA;

HUMANS; LEIOMYOSARCOMA;

EID: 84879888440     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283622c77     Document Type: Review

References (45)

1. Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011; 6:e20294.
2. Farid M, Ong WS, Tan MH, et al. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease. Am J Clin Oncol 2012.
3. Mouaqit O, Belkacem Z, Ifrine L, et al. A rare tumor of the thyroid gland: report on one case of leiomyosarcoma and review of literature. Updates Surg 2013.
4. Park EY, Seo HI, Yun SP, et al. Primary leiomyosarcoma of gallbladder. J Korean Surg Soc 2012; 83:403-407.
5. Croce A, Moretti A, Laus M, Crescenzi D. Leiomyosarcoma of the base of the tongue and free edge of the epiglottis: a case report. J Med Case Rep 2012; 6:400.
6. Takehara K, Aoki H, Takehara Y, et al. Primary hepatic leiomyosarcoma with liver metastasis of rectal cancer. World J Gastroenterol 2012; 18:5479-5484.
7. Elouazzani H, Zouaidia F, Jahid A, et al. Primary endobronchial leiomyosarcoma of the lung: clinical, gross and microscopic findings of two cases. J Clin Imaging Sci 2012; 2:35.
8. Yodonawa S, Ogawa I, Yoshida S, et al. Gastric metastasis from a primary renal leiomyosarcoma. Case Rep Gastroenterol 2012; 6:314-318.
9. Moletta L, Sperti C, Beltrame V, et al. Leiomyosarcoma of the pancreas with liver metastases as a paradigm of multimodality treatment: case report and review of the literature. J Gastrointest Cancer 2012; 43:246.
10. Weiss SW, Goldblum JR. Enzinger and Weiss's soft tissue tumours. 4th ed. St. Louis, Missouri: Mosby; 2001.
11. Gadducci A. Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 2011; 25:783-795.
12. Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous 'leiomyosarcoma'. Am J Surg Pathol 2011; 35:599-607.
13. Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004; 101:1455-1462. (Pubitemid 39180402)
14. Gokaslan H, Turkeri L, Kavak ZN, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest 2005; 59:36-40. (Pubitemid 40082295)
15. Cornejo K, Shi M, Jiang Z. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma. Hum Pathol 2012; 43:1567-1572.
16. Webb EM, Wang ZJ, Westphalen AC, et al. Can CT features differentiate between inferior vena cava leiomyosarcomas and primary retroperitoneal masses? AJR Am J Roentgenol 2013; 200:205-209.
17. Yamane T, Takaoka A, Kita M, et al. 18F-FLT PET performs better than 18FFDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma. Ann Nucl Med 2012; 26:478-484.
18. Kieffer E, Alaoui M, Piette JC, et al. Leiomyosarcoma of the inferior vena cava: experience in 22 cases. Ann Surg 2006; 244:289-295. (Pubitemid 44305545)
19. Fiore M, Colombo C, Locati P, et al. Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava. Ann Surg Oncol 2012; 19:511-518.
20. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008; 112:820-830. (Pubitemid 351240576)
21. Pelmus M, Penault-Llorca F, Guillou L, et al. Prognostic factors in early-stage leiomyosarcoma of the uterus. Int J Gynecol Cancer 2009; 19:385-390.
22. D'angelo E, Espinosa I, Ali R, et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol 2011; 121:328-333.
23. Lusby K, Savannah KB, Demicco EG et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol 2013.
24. Abraham JA, Weaver MJ, Hornick JL, et al. Outcomes and prognostic factors for a consecutive case series of 115 patients with somatic leiomyosarcoma. J Bone Joint Surg Am 2012; 94:736-744.
25. Italiano A, Largarde P, Brulard C, et al. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics. Clin Cancer Res 2013.
26. Mann GN, Mann LV, Levine EA, Shen P. Primary leiomyosarcoma of the inferior vena cava: a 2-institution analysis of outcomes. Surgery 2012; 151:261-267.
27. Massi D, Franchi A, Alos L, et al. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology 2010; 56:251-262.
28. Antonescu CR, Erlandson RA, Huvos AG. Primary leiomyosarcoma of bone: a clinicopathologic, immunohistochemical, and ultrastructural study of 33 patients and a literature review. Am J Surg Pathol 1997; 21:1281-1294. (Pubitemid 27460855)
29. Brewer P, Sumathi V, Grimer RJ, et al. Primary leiomyosarcoma of bone: analysis of prognosis. Sarcoma 2012; 636849.
30. Mahdavi A, Monk BJ, Ragazzo J, et al. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience. Int J Gynecol Cancer 2009; 19:1084.
31. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44:808-818.
32. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113:573-581.
33. Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012; 13:1045-1054.
34. Hensley ML, Wathen JK, Maki RG, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 2013; 119:1555-1561.
35. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11:1276-1285. (Pubitemid 23199130)
36. Van Der Graaf WTA, Judson I, Verweij J, et al. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. In: Program and Abstracts of the 37th European Society for Medical Oncology Congress; 28 September to 2 October 2012; Vienna, Austria. Abstract LBA7; 2012.
37. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20:2824-2831. (Pubitemid 34651511)
38. Demetri GD, Chawla SP, Von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27:4188-4196.
39. Monk BJ, Blessing JA, Street DG, et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 2012; 124:48-52.
40. Garcia-Del-Muro X, Lopez-Pousa A,Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29:2528-2533.
41. Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011; 12:1052.
42. Van Der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic softtissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879-1886.
43. Von Mehren M, Rankin C, Goldblum JR, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 2012; 118:770-776.
44. Verschraegen CF, Arias-Pulido H, Lee SJ, et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol 2012; 23:785-790.
45. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30:78-84.